This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial including 38 adults found a favorable safety profile of atezolizumab plus bevacizumab, with 51.3% progression-free survival at 12 months and durable responses for patients with advanced nonsquamous NSCLC with high tumor mutation burden and no EGFR or ALK genomic alterations. The gene discussed is EGFR; the disease is neoplasm.